Previous studies have reported the co-expression of LAMC2 and EGFR in various cancers including cholangiocarcinoma, anaplastic thyroid carcinoma, and bladder cancer [11, 14, 25]. This evidence concerns the gene EGFR and cholangiocarcinoma.